Pegadricase
- Generic Name
- Pegadricase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1040753-26-1
- Unique Ingredient Identifier
- 50XB37EKN8
- Background
Pegadricase is under investigation in clinical trial NCT01021241 (Safety and Efficacy Study of Intravenous Uricase-PEG 20).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 33
- Registration Number
- NCT04047394
- Locations
- 🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT03905512
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Great Lakes Clinical Trials, Chicago, Illinois, United States
🇺🇸DJL Clinical Research, Charlotte, North Carolina, United States
Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT02959918
- Locations
- 🇺🇸
Tri West Research Associates LLC, El Cajon, California, United States
🇺🇸Omega Research Consultants LLC, DeBary, Florida, United States
🇺🇸East-West Medical Research Institute, Honolulu, Hawaii, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath